Key result
Microfabrication approaches can address the instability, solvent requirements, and low ion channel incorporation efficiency of bilayer lipid membrane systems for drug screening.
Why the study?
Instability, reliance on non-volatile organic solvents, and low ion channel incorporation efficiency have limited the use of bilayer lipid membrane systems as drug screening platforms.
Highlights microfabrication approaches to improve artificial cell membrane systems for ion channel drug screening and personalized medicine.
May advance stable ion channel screening platforms; leaves open clinical translation for personalized medicine.
An artificial cell membrane that is composed of bilayer lipid membranes (BLMs) with transmembrane proteins incorporated within them represents a well-defined system for the analysis of membrane proteins, especially ion channel proteins that are major targets for drug design. Because the BLM system has a high compatibility with recently developed cell-free expression systems, it has attracted attention as a next-generation drug screening system. However, three issues associated with BLM systems, i. e., their instability, the need for non-volatile organic solvents and a low efficiency of ion channel incorporation, have limited their use as a drug screening platform. In this personal account, we discuss our recent approaches to address these issues based on microfabrication. We also discuss the potential for using the BLM system combined with cell-free expression systems as a drug screening system for future personalized medicine.
No takes yet. Share an insight, caveat, or question.
Komiya et al. (2020) reported a review. Bilayer lipid membrane (BLM) systems was evaluated. Microfabrication approaches can address the instability, solvent requirements, and low ion channel incorporation efficiency of bilayer lipid membrane systems for drug screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: